Callan Family Office’s Teradyne TER Stock Holding History

Callan Family Office’s Portfolio TER Stock Details TER Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.21M	Sell	4,562 -169	-4%	-$63.8K	0.04%	363
2026 Q1	$1.4M	Sell	4,731 -24	-0.5%	-$6.69K	0.03%	461
2025 Q4	$920K	Buy	4,755 +1,158	+32%	+$199K	0.02%	571
2025 Q3	$495K	Sell	3,597 -250	-6%	-$27.3K	0.02%	538
2025 Q2	$346K	Buy	+3,847	New	+$307K	0.01%	721

Other funds holding TER

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

Callan Family Office's TER Position: Q2 2026 in Review

Callan Family Office reduced its Teradyne (TER) stake by 3.6% in Q2 2026, selling an estimated $63.8K and leaving 4,562 shares worth $2.21M. The position accounts for 0.04% of the portfolio, ranked #363.

Callan Family Office first reported a position in TER in Q2 2025 and has held it in 5 quarters since. 1,429 funds tracked by Wall St. Rank hold TER as of Q2 2026.

Callan Family Office held 4,562 shares of Teradyne worth $2.21M as of Q2 2026.
Callan Family Office sold 169 Teradyne shares in Q2 2026, an estimated $63.8K.
Teradyne made up 0.04% of Callan Family Office's portfolio in Q2 2026, its #363 holding.
Callan Family Office first reported a position in Teradyne in Q2 2025 and has held it in 5 quarters since.
1,429 funds tracked by Wall St. Rank held Teradyne as of Q2 2026.

Based on Callan Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.